| Unique ID issued by UMIN | UMIN000062227 |
|---|---|
| Receipt number | R000071212 |
| Scientific Title | Exploratory pilot study on Hachimijiogan in prefrail andfrail older adults with nocturia |
| Date of disclosure of the study information | 2026/07/15 |
| Last modified on | 2026/07/13 22:44:30 |
A pilot study on the efficacy of Hachimijiogan for pre-frailty/frailty accompanied by nocturia
Research on Hachimijiogan and Frailty
Exploratory pilot study on Hachimijiogan in prefrail andfrail older adults with nocturia
Research on Hachimijiogan and Frailty
| Japan |
pre-frailty/frailty
| Geriatrics |
Others
NO
The objective of this study is to evaluate the efficacy of Hachimijiogan in treating frailty and pre-frailty in patients who experience two or more nighttime urination episodes and have a JFS score of 4 or higher.
Efficacy
Exploratory
Explanatory
Not applicable
Change in the number of nighttime urination episodes from baseline (after 4 months)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
NO
NO
NO
No need to know
1
Treatment
| Medicine |
Hachimijiogan
| 60 | years-old | <= |
| 85 | years-old | > |
Male and Female
1) Patients receiving treatment at Toyama University Hospital or Hida City Hospital
2) Men and women aged 60 or older but under 85 at the time of obtaining informed consent
3) Patients who have been taking any of the following oral medications for the past two months anticholinergics, beta 3 agonists, or alpha 1 blockers and who experience two or more episodes of nocturia
4) Japan Frailty Scale (JFS) score of 4 or higher
5) Patients capable of walking 5 meters or more
6) Patients who have provided written informed consent
1) Patients taking Japanese taraditional(Kampo) medicine
2) Patients who regularly consume health functional foods that may affect the study at least three times a week and are unable to discontinue their use starting three weeks before the start of the study
3) Patients who have changed the dosage or type of any of the following Western medications within the past two months, which may worsen frequent urination:no specific underlying medical conditions required
a) Diuretics
b) SGLT2 inhibitors
c) Cholinergic agents
d) PDE5 inhibitors
4) Patients with renal impairment (eGFR < 30 mL/min/1.73 m2)
5) Patients with severe hepatic impairment (AST or ALT >= 100 IU/L)
6) Patients with severely impaired walking ability, such as those who require a cane or wheelchair to walk
7) Patients with a sensitive gastrointestinal tract who are prone to diarrhea
8) Patients deemed unsuitable for participation in this study for other reasons, such as having serious complications
40
| 1st name | MOSABURO |
| Middle name | |
| Last name | KAINUMA |
University of Toyama
Deoartment of Japanese Oriental Medicine
9300194
2630 Sugitani Toyama
0764347393
kainuma@med.u-toyama.ac.jp
| 1st name | Mosaburo |
| Middle name | |
| Last name | Kainuma |
University of Toyama
Department of Japanese Oriental Medicine
930-0194
2630 Sugitani Toyama
0764347393
kainuma@med.u-toyama.ac.jp
University of Toayam
None
Self funding
Clinical Reserch Review Board, University of Toyama
2630 Sugitani Toyama
076-415-8857
rinri@adm.u-toyama.ac.jp
NO
| 2026 | Year | 07 | Month | 15 | Day |
Unpublished
Preinitiation
| 2026 | Year | 06 | Month | 01 | Day |
| 2026 | Year | 06 | Month | 10 | Day |
| 2026 | Year | 07 | Month | 22 | Day |
| 2028 | Year | 03 | Month | 31 | Day |
| 2026 | Year | 07 | Month | 13 | Day |
| 2026 | Year | 07 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071212